<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-599
Date of Submission: 2025-01-30

This report was submitted by a Nurse from Smith-Wheeler Medical Center concerning patient ANON-PX-2332. The subject is a 37-year-old other with a significant medical history including atrial fibrillation, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 279mg, initiated on 2025-01-17 for Neuropathic pain with the course ongoing.

On approximately 2025-01-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Anaphylaxis, Vomiting, Somnolence. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Move public artist study. Sound ground study especially coach government. Way oil assume improve approach party.</data>
report_id: ADR-2025-599
report_date: '2025-01-30'
patient_details:
  patient_id: ANON-PX-2332
  gender: Other
  relevant_history:
  - atrial fibrillation
  - chronic kidney disease
  age_at_reaction: 37
suspected_drugs:
- drug_name: Gabapentin
  dosage: 279mg
  route_of_administration: Intravenous
  start_date: '2025-01-17'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Nausea
  onset_date: '2025-01-24'
  severity: Severe
  outcome: Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-01-24'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
- symptom_name: Vomiting
  onset_date: '2025-01-24'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Somnolence
  onset_date: '2025-01-24'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 2
reporting_facility: Smith-Wheeler Medical Center
reporter_type: Nurse
notes: Move public artist study. Sound ground study especially coach government. Way
  oil assume improve approach party.
